Sara Karlovitch

Magrolimab Plus Various Anti-Leukemia Therapies Being Studied for Efficacy in AML

December 14th 2021

Magrolimab plus combinations of various antileukemia therapies are being investigated for their efficacy in first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia.

Ponatinib Elicits Encouraging Activity in TKI-Resistant CP-CML

December 12th 2021

Ponatinib demonstrated high response rates in patients with TKI-resistant, chronic-phase chronic myeloid leukemia, irrespective of T315I mutation status at baseline, according to findings from the phase 2 OPTIC trial.

Adjuvant Approaches Reduce Risk of Distant Recurrence in HER2+ Early Stage Breast Cancer

December 9th 2021

Adjuvant treatment with neratinib or ado-trastuzumab emtansine resulted in a greater reduction in the risk of disease recurrence compared with other therapies in an epidemiologic model of HER2-positive, early-stage breast cancer.

Osimertinib/Bevacizumab Combo Does Not Improve PFS in EGFR-Mutant NSCLC

September 18th 2021

The combination of osimertinib and bevacizumab did not produce a superior progression-free survival benefit vs osimertinib alone in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation.

Perioperative Cabozantinib Yields Promising Results in mRCC

September 18th 2021

Perioperative treatment with cabozantinib induced responses in patients with intermediate and poor-risk metastatic renal cell carcinoma

Ruxolitinib Represents a Key Clinical Tool in Polycythemia Vera Paradigm

September 11th 2021

The JAK1/JAK2 inhibitor ruxolitinib has several clinical uses in the treatment of patients with polycythemia vera and plays an especially important role in adult patients who have had an inadequate response to hydroxyurea.

Venetoclax Plus FLAG-IDA Elicits High and Durable Responses in Newly Diagnosed AML

September 9th 2021

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

Regorafenib/Nivolumab Found to be More Effective in Japanese Population vs North American in CRC

June 9th 2021

Regorafenib/Avelumab Combo Elicits Modest Activity in Heavily Pretreated Biliary Tract Cancer

June 8th 2021

The addition of regorafenib to avelumab demonstrated modest anti-tumor responses and survival benefit in patients with heavily pretreated biliary tract cancer.

Niraparib Individualized Starting Dose Tolerable in Platinum-Sensitive Recurrent Ovarian Cancer

June 5th 2021

Niraparib, when delivered at an individualized starting dose, was found to be well tolerated in patients with platinum-sensitive recurrent ovarian cancer.

Telisotuzumab Vedotin Demonstrates Efficacy and Tolerability in Previously Treated c-MET+ NSCLC

April 13th 2021

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer.

Unanswered Questions Remain in Frontline NSCLC

July 16th 2019

Lecia V. Sequist, MD, MPH, highlights recent developments in NSCLC treatment and shared key questions that still need to be addressed.

Research Abounds Across Lymphomas, But More Work Remains

July 11th 2019

Jing-Zhou Hou, MD, PhD, highlights the research being conducted in the realm of lymphoma, including positive and negative trials that have read out in the space, and provides insight into novel approaches under investigation.